Journal of Allergy and Clinical Immunology: Global (Nov 2024)
Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis
- Makiko Kido-Nakahara, MD,
- Daisuke Onozuka, PhD,
- Kenji Izuhara, PhD,
- Hidehisa Saeki, MD,
- Satoshi Nunomura, PhD,
- Motoi Takenaka, MD,
- Mai Matsumoto, MD,
- Yoko Kataoka, MD,
- Rai Fujimoto, MD,
- Sakae Kaneko, MD,
- Eishin Morita, MD,
- Akio Tanaka, MD,
- Michihiro Hide, MD,
- Tatsuro Okano, MD,
- Tomomitsu Miyagaki, MD,
- Natsuko Aoki, MD,
- Kimiko Nakajima, MD,
- Susumu Ichiyama, MD,
- Kyoko Tonomura, MD,
- Yukinobu Nakagawa, MD,
- Risa Tamagawa-Mineoka, MD,
- Koji Masuda, MD,
- Takuya Takeichi, MD,
- Masashi Akiyama, MD,
- Yozo Ishiuji, MD,
- Michie Katsuta, MD,
- Yuki Kinoshita, MD,
- Chiharu Tateishi, MD,
- Aya Yamamoto, MD,
- Akimichi Morita, MD,
- Haruna Matsuda-Hirose, MD,
- Yutaka Hatano, MD,
- Hiroshi Kawasaki, MD,
- Keiji Tanese, MD,
- Mamitaro Ohtsuki, MD,
- Koji Kamiya, MD,
- Yudai Kabata, MD,
- Riichiro Abe, MD,
- Hiroshi Mitsui, MD,
- Tatsuyoshi Kawamura, MD,
- Gaku Tsuji, MD,
- Masutaka Furue, MD,
- Norito Katoh, MD,
- Takeshi Nakahara, MD
Affiliations
- Makiko Kido-Nakahara, MD
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Corresponding author: Makiko Kido-Nakahara, MD, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
- Daisuke Onozuka, PhD
- Department of Oral Microbe Control, Graduate School of Medicine, Osaka University, Osaka, Japan
- Kenji Izuhara, PhD
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan
- Hidehisa Saeki, MD
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan
- Satoshi Nunomura, PhD
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan
- Motoi Takenaka, MD
- Department of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Mai Matsumoto, MD
- Department of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Yoko Kataoka, MD
- Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan
- Rai Fujimoto, MD
- Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan
- Sakae Kaneko, MD
- Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan
- Eishin Morita, MD
- Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan
- Akio Tanaka, MD
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Michihiro Hide, MD
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Tatsuro Okano, MD
- Department of Dermatology, St. Marianna University School of Medicine, Kanagawa, Japan
- Tomomitsu Miyagaki, MD
- Department of Dermatology, St. Marianna University School of Medicine, Kanagawa, Japan
- Natsuko Aoki, MD
- Department of Dermatology, Kochi Medical School, Kochi, Japan
- Kimiko Nakajima, MD
- Department of Dermatology, Kochi Medical School, Kochi, Japan
- Susumu Ichiyama, MD
- Department of Dermatology, Nippon Medical School, Tokyo, Japan
- Kyoko Tonomura, MD
- Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- Yukinobu Nakagawa, MD
- Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- Risa Tamagawa-Mineoka, MD
- Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
- Koji Masuda, MD
- Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
- Takuya Takeichi, MD
- Department of Dermatology, Nagoya University Graduate School of Medicine, Aichi, Japan
- Masashi Akiyama, MD
- Department of Dermatology, Nagoya University Graduate School of Medicine, Aichi, Japan
- Yozo Ishiuji, MD
- Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan
- Michie Katsuta, MD
- Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan
- Yuki Kinoshita, MD
- Department of Dermatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- Chiharu Tateishi, MD
- Department of Dermatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- Aya Yamamoto, MD
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
- Akimichi Morita, MD
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
- Haruna Matsuda-Hirose, MD
- Department of Dermatology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan
- Yutaka Hatano, MD
- Department of Dermatology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan
- Hiroshi Kawasaki, MD
- Department of Dermatology, School of Medicine, Keio University, Tokyo, Japan
- Keiji Tanese, MD
- Department of Dermatology, School of Medicine, Keio University, Tokyo, Japan
- Mamitaro Ohtsuki, MD
- Department of Dermatology, Jichi Medical University, Tochigi, Japan
- Koji Kamiya, MD
- Department of Dermatology, Jichi Medical University, Tochigi, Japan
- Yudai Kabata, MD
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- Riichiro Abe, MD
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- Hiroshi Mitsui, MD
- Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
- Tatsuyoshi Kawamura, MD
- Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
- Gaku Tsuji, MD
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Masutaka Furue, MD
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Norito Katoh, MD
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Takeshi Nakahara, MD
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Journal volume & issue
-
Vol. 3,
no. 4
p. 100317
Abstract
Background: Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti–IL-4Rα antibody, have been developed in recent years. We need to predict which agent is the best choice for each patient, but this remains difficult. Objective: Our aim was to examine clinical background factors and baseline biomarkers that could predict the achievement of improved clinical outcomes in patients with AD treated with dupilumab. Methods: A multicenter, prospective observational study was conducted on 110 patients with AD. The Eczema Area and Severity Index was used as an objective assessment, and the Patient-Oriented Eczema Measure and Numerical Rating Scale for Pruritus were used as patient-reported outcomes. In addition, some clinical background factors were evaluated. Results: The achievement of an absolute Eczema Area and Severity Index of 7 or less was negatively associated with current comorbidity of food allergy and baseline serum lactate dehydrogenase (LDH) levels. There were negative associations between achievement of a Patient-Oriented Eczema Measure score of 7 or less and duration of severe AD and between achievement of an itching Numerical Rating Scale for Pruritus score of 1 or less and current comorbidity of allergic conjunctivitis or baseline serum periostin level. Furthermore, signal detection analysis showed that a baseline serum LDH level less than 328 U/L could potentially be used as a cutoff value for predicting the efficacy of dupilumab. Conclusion: Baseline biomarkers such as LDH and periostin and clinical background factors such as current comorbidity of food allergy and a long period of severe disease may be useful indicators when choosing dupilumab for systemic treatment for AD, as they can predict the efficacy of dupilumab.
